LY3287104
Phase 1
Eli LillyLY3287104 is one of 42 therapeutic programs targeting Liver Cancer. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
261 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Nexavar
BayerPhase 3
Eloxatin
TevaPhase 3
Adriamycin
PfizerPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Imjudo
AstraZenecaPhase 3
Gemzar
Johnson & JohnsonPhase 3
Megace
Bristol-Myers SquibbPhase 3
Bayer Aspirin
BayerPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for LY3287104. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1
- Company